Provided by Tiger Trade Technology Pte. Ltd.

Aligos Therapeutics, Inc.

1.22
-0.0300-2.40%
Post-market: 1.17-0.0499-4.09%19:51 EST
Volume:106.84K
Turnover:133.51K
Market Cap:7.62M
PE:-0.19
High:1.34
Open:1.26
Low:1.18
Close:1.25
52wk High:13.69
52wk Low:1.18
Shares:6.24M
Float Shares:3.77M
Volume Ratio:1.14
T/O Rate:2.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.3682
EPS(LYR):-2.4500
ROE:-159.46%
ROA:-57.76%
PB:0.67
PE(LYR):-0.50

Loading ...

Immunovant Q2 Net Loss Narrows on Lower R&D Costs

Reuters
·
Nov 09

Praxis Precision Q3 Net Loss Widens to $94 Mln on G&A Costs

Reuters
·
Nov 09

Editas Medicine Q3 Net Loss Narrows

Reuters
·
Nov 09

Turn Therapeutics Q3 Net Loss Widens on Higher R&D, Non-Operating Charges

Reuters
·
Nov 09

Aligos Therapeutics Q3 EPS $(2.09) Beats $(2.28) Estimate, Sales $2.830M Miss $5.543M Estimate

Benzinga Earnings
·
Nov 06

Aligos Therapeutics reports Q3 EPS ($2.09), consensus ($2.53)

TIPRANKS
·
Nov 06

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

THOMSON REUTERS
·
Nov 06

Aligos Therapeutics, Inc.: Topline Data for Both Hbeag+ and Hbeag- Cohorts are Expected in Late Q3 2027

THOMSON REUTERS
·
Nov 06

Aligos Therapeutics Q3 EPS USD -2.09 VS. Ibes Estimate USD -2.17

THOMSON REUTERS
·
Nov 06

Aligos Reports Reduced Inflammatory Cytokines in Hepatitis B Study of Pevifoscorvir Sodium

Reuters
·
Nov 06

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026

GlobeNewswire
·
Nov 06

H.C. Wainwright Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)

TIPRANKS
·
Nov 03

Press Release: Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026

Dow Jones
·
Oct 28

Aligos Therapeutics to Present New Pevifoscorvir Sodium Clinical Data in Chronic Hepatitis B at AASLD Liver Meeting 2026

Reuters
·
Oct 06

Aligos Therapeutics Amends Long-Term Headquarters Lease Agreement

TIPRANKS
·
Sep 16

U.S. Research Roundup-Ciena Corp, Docusign, Snowflake

Reuters
·
Sep 04

Aligos Therapeutics to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 02

Aligos Hepatitis B Trial Completion: What Phase 1 Liver Data Mean for ALGS Investors

TIPRANKS
·
Aug 22

Aligos Says Partner Amoytop Doses First Participant in Phase 1 Trial of HBV Drug ALG-170675 in China

Reuters
·
Aug 13

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of Its Potentially Best-in-Class Antisense Oligonucleotide Alg-170675 by Its Partner Amoytop in China

THOMSON REUTERS
·
Aug 13